No black box warning on record for Zyprexa Relprevv

As of the latest FDA labeling reviewed, Zyprexa Relprevv (OLANZAPINE PAMOATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Zyprexa Relprevv medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Elderly Patients with Dementia-Related Psychosis: Increased risk of death and increased incidence of cerebrovascular adverse events (e.g. stroke, transient ischemic attack). ( 5.3 ) Suicide: The possibility of a suicide attempt is inherent in schizophrenia, and close supervision of high-risk patients should accompany drug therapy. ( 5.4 ) Neuroleptic Malignant Syndrome:

No black box warning on record for Zyprexa Relprevv

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Elderly Patients with Dementia-Related Psychosis: Increased risk of death and increased incidence of cerebrovascular adverse events (e.g. stroke, transient ischemic attack). ( 5.3 ) Suicide: The possibility of a suicide attempt is inherent in schizophrenia, and close supervision of high-risk patients should accompany drug therapy. ( 5.4 ) Neuroleptic Malignant Syndrome:

Zyprexa Relprevv Black Box Warning

No black box warning on record for Zyprexa Relprevv

Other warnings & precautions

Zyprexa Relprevv Black Box Warning

No black box warning on record for Zyprexa Relprevv

Other warnings & precautions